Skip to main navigation Skip to search Skip to main content

A systematic literature review of evidence-based clinical practice for rare diseases: What are the perceived and real barriers for improving the evidence and how can they be overcome?

  • Ana Rath
  • , Valérie Salamon
  • , Sandra Peixoto
  • , Virginie Hivert
  • , Martine Laville
  • , Berenice Segrestin
  • , Edmund A.M. Neugebauer
  • , Michaela Eikermann
  • , Vittorio Bertele
  • , Silvio Garattini
  • , Jørn Wetterslev
  • , Rita Banzi
  • , Janus C. Jakobsen
  • , Snezana Djurisic*
  • , Christine Kubiak
  • , Jacques Demotes-Mainard
  • , Christian Gluud
  • *Corresponding author for this work

Research output: Contribution to journalReviewResearchpeer-review

Abstract

Background: Evidence-based clinical practice is challenging in all fields, but poses special barriers in the field of rare diseases. The present paper summarises the main barriers faced by clinical research in rare diseases, and highlights opportunities for improvement. Methods: Systematic literature searches without meta-analyses and internal European Clinical Research Infrastructure Network (ECRIN) communications during face-to-face meetings and telephone conferences from 2013 to 2017 within the context of the ECRIN Integrating Activity (ECRIN-IA) project. Results: Barriers specific to rare diseases comprise the difficulty to recruit participants because of rarity, scattering of patients, limited knowledge on natural history of diseases, difficulties to achieve accurate diagnosis and identify patients in health information systems, and difficulties choosing clinically relevant outcomes. Conclusions: Evidence-based clinical practice for rare diseases should start by collecting clinical data in databases and registries; defining measurable patient-centred outcomes; and selecting appropriate study designs adapted to small study populations. Rare diseases constitute one of the most paradigmatic fields in which multi-stakeholder engagement, especially from patients, is needed for success. Clinical research infrastructures and expertise networks offer opportunities for establishing evidence-based clinical practice within rare diseases.

Original languageEnglish
Article number556
JournalTrials
Volume18
Issue number1
DOIs
Publication statusPublished - 22 Nov 2017

Funding

1Funded by the European Union Framework Programme 7 (EU FP7; grant agreement no. 284395), ECRIN-IA involved 23 countries and brought together diverse stakeholders to overcome barriers to clinical research in three particularly difficult areas (rare diseases, medical devices, and nutrition). Specifically, the project aimed to develop tools, services, and infrastructure to facilitate multinational clinical research in Europe, and to support the development of pan-European disease networks to drive clinical projects. This in turn was intended to improve Europe’s attractiveness to industry, boost its scientific competitiveness, and result in better healthcare for European citizens. Originally planned for 4 years (2012 to 2015), the clinical trials work package was extended until 2017. The EU FP7 grant supporting the ECRIN-IA (GA 284395) provided support for meetings and is acknowledged for making the present paper possible. The Mario Negri Institute is thanked for housing the ECRIN-IA meeting in February 2013. All participants of ECRIN-IA are acknowledged for participating in discussions identifying the barriers and threats to the conduct of RCTs. Sarah Louise Klingenberg, the Trial Search Coordinator of The Cochrane Hepato-Biliary Group at The Copenhagen Trial Unit, is thanked for conducting the academic literature searches. The present review is founded by the European Commission through a grant awarded for the European Clinical Research Infrastructure Network-Integrated Activity project. Project reference: 284395. Funded under: FP7-INFRASTRUCTURES. The funding sources had no influence on data collection, design, analysis, interpretation, or any aspect pertinent to the study.

Keywords

  • Assessment
  • ECRIN
  • European Clinical Infrastructure Networks
  • Evidence-based clinical practice
  • Evidence-based medicine
  • Randomised clinical trials
  • Rare diseases
  • Specific barriers

Fingerprint

Explore the research areas of 'A systematic literature review of evidence-based clinical practice for rare diseases: What are the perceived and real barriers for improving the evidence and how can they be overcome?'.

Cite this